A New Horizon for ALS Patients The Amyotrophic Lateral Sclerosis (ALS) community has received promising news as Otsuka Pharmaceutical announced the top-line results from its Phase 3 FUSION clinical trial. The study evaluated the efficacy and safety of ulefnersen, an investigational treatment designed to address the underlying challenges faced by patients living with this neurodegenerative…